Johnson & Johnson
NYQ: JNJLive Quote
📈 ZcoreAI Score
Our AI model analyzes Johnson & Johnson's price action across multiple timeframes using regression channels and statistical scoring.
Get JNJ Z-Score →About Johnson & Johnson
Healthcare
Drug Manufacturers - General
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
📊 Fundamental Analysis
Johnson & Johnson demonstrates exceptional profitability, with a profit margin of 28.5%.
The company recently reported 9.1% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is 35.0%, which reflects exceptional capital efficiency.
At a current price of $238.46, JNJ currently trades near the top of its 52-week range (87%) (Range: $146.12 - $251.71).
💰 Valuation Insight
JNJ is valued broadly in line with the sector at a PE of 21.60. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
🔴
Debt/Equity
Elevated
⚠️
Revenue Growth
Moderate
✅
Return on Equity
Excellent
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$574.66B
Trailing P/E
21.60
Forward P/E
18.94
Beta (5Y)
0.33
52W High
$251.71
52W Low
$146.12
Avg Volume
8.70M
Day High
Day Low